Placental Tissue Amendments

Summary

The bill mandates that any Utah health care provider who uses after‑birth placental stem cells or other human tissue products in a therapy not approved by the FDA must give patients a clear written notice, display it in the office, and obtain a signed consent form. Suppliers must also receive written confirmation that the provider will provide the notice. The rule does not apply to providers with FDA investigational approvals or those operating under certain accredited institutions.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share